CVS Group profit drops 7.4% as revenue rises on Australia expansion, asset sale
NEW YORK - OrganOx Ltd. has received U.S. Food and Drug Administration approval for air transport of its metra® normothermic machine perfusion device, the company announced in a press release.
The approval allows transplant centers and organ procurement organizations to transport donor livers on the metra® device via chartered aircraft, extending the geographic reach of the technology across the United States.
The metra® system keeps donor livers in a metabolically active state outside the body, which enables longer preservation times and functional assessment prior to transplant. According to the company, this capability could potentially increase the number of viable organs available for transplantation.
"This FDA approval is a major step forward for the transplant community," said Craig Marshall, CEO of OrganOx. "By enabling air transport of donor livers on the metra®, we’re removing key logistical barriers to broader organ utilization."
The company has partnered with Strata Critical Medical (NASDAQ:SRTA) to provide dedicated air and ground transportation support for the device. With a market capitalization of $448.5 million and strong liquidity position, SRTA has seen impressive momentum, gaining over 23% in the past week and trading near its 52-week high. According to InvestingPro analysis, the stock appears overvalued at current levels, though it maintains a "Good" financial health score. Scott Wunsch, CEO of Trinity Medical Solutions, the logistics division of Strata Critical, described the partnership as creating "a turnkey solution for transplant centers and OPOs to leverage this technology."Discover more insights about SRTA and 1,400+ other stocks with InvestingPro’s comprehensive research reports, featuring detailed financial analysis and expert recommendations.
OrganOx’s metra® system has been used in over 6,000 liver transplants to date and is approved in the United States, Europe, Canada, and Australia, according to the company. The partnership with SRTA, which maintains a healthy balance sheet with more cash than debt, positions both companies to capitalize on the growing medical logistics market.
The company anticipates increased adoption among U.S. transplant programs seeking to optimize outcomes while managing operational complexity.
In other recent news, Blade Air Mobility disclosed its second-quarter 2025 earnings, showcasing a mixed performance. The company reported an earnings per share (EPS) of -$0.05, which was a 7.76% miss compared to the anticipated -$0.0464. On a positive note, Blade Air Mobility’s revenue for the quarter reached $70.8 million, exceeding expectations by 10.49%. These figures reflect the company’s ability to generate higher-than-expected revenue despite falling short on earnings. The recent developments highlight the ongoing challenges and opportunities faced by Blade Air Mobility. Investors and analysts will likely keep a close watch on the company’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.